Overactive bladder in an integrated delivery system: a longitudinal cohort study.
Anticholinergic burden
Antimuscarinics
Electronic health records
Integrated delivery system
Medication and procedure use
Overactive bladder
Overactive bladder syndrome
Primary and specialty care
Urgency
Urinary incontinence
Journal
BMC health services research
ISSN: 1472-6963
Titre abrégé: BMC Health Serv Res
Pays: England
ID NLM: 101088677
Informations de publication
Date de publication:
20 May 2020
20 May 2020
Historique:
received:
14
08
2018
accepted:
10
05
2020
entrez:
22
5
2020
pubmed:
22
5
2020
medline:
15
12
2020
Statut:
epublish
Résumé
Overactive bladder (OAB) is common and morbid. Medication and diagnosis claims may be specific, but lack sensitivity to identify patients with overactive bladder. We used an "electronic health record (EHR) phenotype" to identify cases and describe treatment choices and anticholinergic burden for OAB. We conducted a retrospective cohort study in a large, integrated health delivery system between July 2011 and June 2012 (2-year follow-up). We examined care from primary care and specialty clinics, medication and procedure use, and anticholinergic burden for each patient. There were 7362 patients with an EHR OAB phenotype; 50% of patients were > 65 years old, 74% were female, and 83% were white. The distribution of care included primary care physician (PCP)/specialty co-management (25% of patients); PCP care only (18%); urology only (13%); or some other combination of specialty care (33%). Only 40% of patients were prescribed at least 1 OAB medication during the study. The mean duration of prescribed medication was 1.5 months (95% confidence interval [CI], 1.4 to 1.6 months; range, < 1 month to 24 months). Independent predictors of receipt of an OAB medication included increasing age (odds ratio [OR], 1.4 for every 10 years; 95% CI, 1.4 to 1.5), women (OR, 1.6 compared with men; 95% CI, 1.4 to 1.8), diabetes (OR, 1.3; 95% CI, 1.1 to 1.5), and certain sources of care compared with PCP-only care: PCP/specialty co-management (OR, 1.8; 95% CI, 1.5 to 2.0), urology (OR, 2.2; 95% CI, 1.8 to 2.6), and multiple specialists (OR, 1.4; 95% CI, 1.2 to 1.8). Very few patients received other treatments: biofeedback (< 1%), onabotulinumtoxinA (2%), or sacral nerve stimulation (1%). Patients who received OAB medications had significantly higher anticholinergic burden than patients who did not (anticholinergic total standardized daily dose, 125 versus 46; P < .001). Although OAB is common and morbid, in a longitudinal study using an EHR OAB phenotype 40% of patients were treated with OAB medication and only briefly.
Sections du résumé
BACKGROUND
BACKGROUND
Overactive bladder (OAB) is common and morbid. Medication and diagnosis claims may be specific, but lack sensitivity to identify patients with overactive bladder. We used an "electronic health record (EHR) phenotype" to identify cases and describe treatment choices and anticholinergic burden for OAB.
METHODS
METHODS
We conducted a retrospective cohort study in a large, integrated health delivery system between July 2011 and June 2012 (2-year follow-up). We examined care from primary care and specialty clinics, medication and procedure use, and anticholinergic burden for each patient.
RESULTS
RESULTS
There were 7362 patients with an EHR OAB phenotype; 50% of patients were > 65 years old, 74% were female, and 83% were white. The distribution of care included primary care physician (PCP)/specialty co-management (25% of patients); PCP care only (18%); urology only (13%); or some other combination of specialty care (33%). Only 40% of patients were prescribed at least 1 OAB medication during the study. The mean duration of prescribed medication was 1.5 months (95% confidence interval [CI], 1.4 to 1.6 months; range, < 1 month to 24 months). Independent predictors of receipt of an OAB medication included increasing age (odds ratio [OR], 1.4 for every 10 years; 95% CI, 1.4 to 1.5), women (OR, 1.6 compared with men; 95% CI, 1.4 to 1.8), diabetes (OR, 1.3; 95% CI, 1.1 to 1.5), and certain sources of care compared with PCP-only care: PCP/specialty co-management (OR, 1.8; 95% CI, 1.5 to 2.0), urology (OR, 2.2; 95% CI, 1.8 to 2.6), and multiple specialists (OR, 1.4; 95% CI, 1.2 to 1.8). Very few patients received other treatments: biofeedback (< 1%), onabotulinumtoxinA (2%), or sacral nerve stimulation (1%). Patients who received OAB medications had significantly higher anticholinergic burden than patients who did not (anticholinergic total standardized daily dose, 125 versus 46; P < .001).
CONCLUSIONS
CONCLUSIONS
Although OAB is common and morbid, in a longitudinal study using an EHR OAB phenotype 40% of patients were treated with OAB medication and only briefly.
Identifiants
pubmed: 32434511
doi: 10.1186/s12913-020-05315-1
pii: 10.1186/s12913-020-05315-1
pmc: PMC7238545
doi:
Substances chimiques
Cholinergic Antagonists
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
447Subventions
Organisme : Astellas Pharma US
ID : NA
Références
Eur J Clin Pharmacol. 2009 Mar;65(3):309-14
pubmed: 19107469
JAMA Intern Med. 2015 Mar;175(3):401-7
pubmed: 25621434
Urology. 2011 Jan;77(1):55-9
pubmed: 20970839
Int J Med Sci. 2010 Nov 12;7(6):391-4
pubmed: 21103074
J Gen Intern Med. 2010 Apr;25(4):284-90
pubmed: 20131023
Int J Clin Pract. 2011 May;65(5):567-85
pubmed: 21489081
Eur Urol. 2010 Apr;57(4):586-91
pubmed: 20036783
Pharmacotherapy. 2016 Nov;36(11):1123-1131
pubmed: 27711982
Eur J Clin Pharmacol. 2011 May;67(5):535-6
pubmed: 21061118
Neurology. 2010 Jul 13;75(2):152-9
pubmed: 20625168
BMJ. 2015 Apr 24;350:h1885
pubmed: 25911572
J Urol. 2012 Dec;188(6 Suppl):2455-63
pubmed: 23098785
BJU Int. 2011 Nov;108(9):1459-71
pubmed: 21371240
Rev Urol. 2008 Winter;10(1):6-13
pubmed: 18470275
BJU Int. 2001 Jun;87(9):760-6
pubmed: 11412210
Int Urogynecol J. 2017 Aug;28(8):1249-1256
pubmed: 28091711
World J Urol. 2003 May;20(6):327-36
pubmed: 12811491
Curr Med Res Opin. 2007 Jan;23(1):65-76
pubmed: 17257467
Clin Ther. 2013 Nov;35(11):1744-51
pubmed: 24091072
JAMA Neurol. 2016 Jun 1;73(6):721-32
pubmed: 27088965
J Am Med Inform Assoc. 2013 Dec;20(e2):e206-11
pubmed: 24302669
J Gerontol A Biol Sci Med Sci. 2009 Apr;64(4):492-8
pubmed: 19196642
Can J Urol. 2014 Jun;21 Suppl 2:2-11
pubmed: 24978628
BJU Int. 2012 Dec;110(11):1767-74
pubmed: 22409769
Stat Med. 1997 Feb 28;16(4):385-95
pubmed: 9044528
Fam Pract. 2001 Feb;18(1):48-52
pubmed: 11145628
J Urol. 2018 Mar;199(3):779-784
pubmed: 28965782
J Manag Care Spec Pharm. 2016 Apr;22(4):406-13
pubmed: 27023694